PMID- 37621757
OWN - NLM
STAT- MEDLINE
DCOM- 20230828
LR  - 20230828
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 29
IP  - 29
DP  - 2023 Aug 7
TI  - Predictors and optimal management of tumor necrosis factor antagonist nonresponse 
      in inflammatory bowel disease: A literature review.
PG  - 4481-4498
LID - 10.3748/wjg.v29.i29.4481 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) antagonists, the first biologics approved for 
      treating patients with inflammatory bowel disease (IBD), are effective for the 
      induction and maintenance of remission and significantly improving prognosis. 
      However, up to one-third of treated patients show primary nonresponse (PNR) to 
      anti-TNF-alpha therapies, and 23%-50% of IBD patients experience loss of response 
      (LOR) to these biologics during subsequent treatment. There is still no 
      recognized predictor for evaluating the efficacy of anti-TNF drugs. This review 
      summarizes the existing predictors of PNR and LOR to anti-TNF in IBD patients. 
      Most predictors remain controversial, and only previous surgical history, disease 
      manifestations, drug concentrations, antidrug antibodies, serum albumin, some 
      biologic markers, and some genetic markers may be potentially predictive. In 
      addition, we also discuss the next steps of treatment for patients with PNR or 
      LOR to TNF antagonists. Therapeutic drug monitoring plays an important role in 
      treatment selection. Dose escalation, combination therapy, switching to a 
      different anti-TNF drug, or switching to a biologic with a different mechanism of 
      action can be selected based on the concentration of the drug and/or antidrug 
      antibodies.
CI  - (c)The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Wang, Liang-Fang
AU  - Wang LF
AD  - Department of Gastroenterology and Hepatology, West China Hospital, Sichuan 
      University, Chengdu 610041, Sichuan Province, China.
AD  - West China School of Medicine, Sichuan University, Chengdu 610041, Sichuan 
      Province, China.
FAU - Chen, Ping-Run
AU  - Chen PR
AD  - Department of Gastroenterology and Hepatology, West China Hospital, Sichuan 
      University, Chengdu 610041, Sichuan Province, China.
AD  - West China School of Medicine, Sichuan University, Chengdu 610041, Sichuan 
      Province, China.
FAU - He, Si-Ke
AU  - He SK
AD  - West China School of Medicine, Sichuan University, Chengdu 610041, Sichuan 
      Province, China.
FAU - Duan, Shi-Hao
AU  - Duan SH
AD  - Department of Gastroenterology and Hepatology, West China Hospital, Sichuan 
      University, Chengdu 610041, Sichuan Province, China.
AD  - West China School of Medicine, Sichuan University, Chengdu 610041, Sichuan 
      Province, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Department of Gastroenterology and Hepatology, West China Hospital, Sichuan 
      University, Chengdu 610041, Sichuan Province, China.
AD  - West China School of Medicine, Sichuan University, Chengdu 610041, Sichuan 
      Province, China. hxzyan@163.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 0 (Antibodies)
RN  - 0 (Biological Products)
SB  - IM
MH  - Humans
MH  - Tumor Necrosis Factor Inhibitors/therapeutic use
MH  - Antibodies
MH  - Combined Modality Therapy
MH  - *Inflammatory Bowel Diseases/drug therapy
MH  - *Biological Products/adverse effects
PMC - PMC10445007
OTO - NOTNLM
OT  - Inflammatory bowel disease
OT  - Management
OT  - Predictor
OT  - Primary nonresponse
OT  - Secondary nonresponse
OT  - Tumor necrosis factor antagonist
COIS- Conflict-of-interest statement: Authors declare no conflict of interests for this 
      article.
EDAT- 2023/08/25 06:42
MHDA- 2023/08/28 06:43
PMCR- 2023/08/07
CRDT- 2023/08/25 03:52
PHST- 2023/03/23 00:00 [received]
PHST- 2023/06/28 00:00 [revised]
PHST- 2023/07/17 00:00 [accepted]
PHST- 2023/08/28 06:43 [medline]
PHST- 2023/08/25 06:42 [pubmed]
PHST- 2023/08/25 03:52 [entrez]
PHST- 2023/08/07 00:00 [pmc-release]
AID - 10.3748/wjg.v29.i29.4481 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2023 Aug 7;29(29):4481-4498. doi: 
      10.3748/wjg.v29.i29.4481.